ReviewPLoS genetics2016
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer.
Review in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 135 citations in OpenAlex.
- Deacetylase-independent HDAC1 condensation defines temozolomide response in glioblastoma.Nature chemical biology · 2026Article
- Integrated transcriptome analysis and machine learning to construct a homeostatic model of acetylation for bladder cancer and validate the key geneTranslational andrology and urology · 2026Article
- Comparative Serum Proteomic Analysis of Different Habitual Coffee Consumption Among Healthy and Obese with and Without Hypertension Groups.Current issues in molecular biology · 2026Article
- KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer.Cancer chemotherapy and pharmacology · 2026Article
- Structural and Functional Studies on Key Epigenetic Regulators in Asthma.Biomolecules · 2025Review
- Integrated transcriptome analysis and combinatorial machine learning to construct a homeostatic model of acetylation for ccRCC and validate the key gene GCNT4.Cancer cell international · 2025Article
- Chronic stress contributes to long-term isoflurane anesthesia-induced cognitive dysfunction via histone acetylation modulated by RbAp48-HDAC2 in male mice.Journal of anesthesia and translational medicine · 2025Article
- Phosphoinositide signaling in the nucleus: Impacts on chromatin and transcription regulation.Biology of the cell · 2025Review
- Lactate and lactylation: emerging roles in autoimmune diseases and metabolic reprogramming.Frontiers in immunology · 2025Review
- Histone and Non-histone Reversible Acetylation in Development, Aging, and Disease.Results and problems in cell differentiation · 2025Review
- Dysregulation of lysine acetylation in the pathogenesis of digestive tract cancers and its clinical applications.Frontiers in cell and developmental biology · 2024Review
- Article
- PARylated PDHE1α generates acetyl-CoA for local chromatin acetylation and DNA damage repair.Nature structural & molecular biology · 2023Article
- Experimental Insights into the Interplay between Histone Modifiers and p53 in Regulating Gene Expression.International journal of molecular sciences · 2023Review
- Inflammatory Cells Can Alter the Levels of H3K9ac and γH2AX in Dysplastic Cells and Favor Tumor Phenotype.Journal of personalized medicine · 2023Article
- Protein post-translational modifications in the regulation of cancer hallmarks.Cancer gene therapy · 2023Review
- Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.BMC medical genomics · 2022Article
- Article
- LINC00467: an oncogenic long noncoding RNA.Cancer cell international · 2022Review
- Lysine Crotonylation: An Emerging Player in DNA Damage Response.Biomolecules · 2022Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chromatin-based DNA damage response (DDR) pathways are fundamental for preventing genome and epigenome instability, which are prevalent in cancer. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyze the addition and removal of acetyl groups on lysine residues, a post-translational modification important for the DDR. Acetylation can alter chromatin structure as well as function by providing binding signals for reader proteins containing acetyl-lysine recognition domains, including the bromodomain (BRD). Acetylation dynamics occur upon DNA damage in part to regulate chromatin and BRD protein interactions that mediate key DDR activities. In cancer, DDR and acetylation pathways are often mutated or abnormally expressed. DNA damaging agents and drugs targeting epigenetic regulators, including HATs, HDACs, and BRD proteins, are used or are being developed to treat cancer. Here, we discuss how histone acetylation pathways, with a focus on acetylation reader proteins, promote genome stability and the DDR. We analyze how acetylation signaling impacts the DDR in the context of cancer and its treatments. Understanding the relationship between epigenetic regulators, the DDR, and chromatin is integral for obtaining a mechanistic understanding of genome and epigenome maintenance pathways, information that can be leveraged for targeting acetylation signaling, and/or the DDR to treat diseases, including cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.